IFEX

LOE Approaching

ifosfamide

NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT06156410Phase 1Recruiting

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Started Oct 2023
30 enrolled
Ewing SarcomaOsteosarcomaSarcomas
NCT05364424Phase 1Completed

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Started Nov 2022
43 enrolled
Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04833114Phase 3Active Not Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Started Apr 2021
306 enrolled
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
NCT04665765Phase 2Active Not Recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Started Jan 2021
NCT04408937Phase 1Completed

The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.

Started May 2020
89 enrolled
Liver Disease